09 January 2023 – PLC is proud to announce it has successfully filed the NRL-1049 Investigational New Drug (IND) application to the US FDA on behalf of Neurelis. PLC has supported Neurelis with their Regulatory filings for NRL-1049 from inception.
NEURELIS ANNOUNCES FILING OF ITS INVESTIGATIONAL NEW DRUG APPLICATION FOR NRL-1049, A RHO KINASE (ROCK) INHIBITOR WITH POTENTIAL TO TREAT CEREBRAL CAVERNOUS MALFORMATIONS
- Pre-clinical data recently presented at Society for Neuroscience’s annual meeting demonstrates NRL-1049 potential safety, Neurelis to advance further studies
